Search Results
Results found for "Confo Therapeutics"
- High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and...
particularly aggressive and heterogeneous disease with few effective targeted therapies and precision therapeutic
- GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response to...
and stabilizing IGF1R, and suggests that it may serve as a valuable prognostic factor and potential therapeutic
- Crinetics Pharmaceuticals announced the formation of an independently operated new company...
stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics
- 🎄 Have Yourself a Merry Little GPCRmas! ❄ Dec 9 - 15, 2024
Pharmacology GPCR Jobs GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic
- Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19...
Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics
- From Farm Fields to GPCR Discovery, GLP-1 and GIP
The Future of GPCR Therapeutics in Metabolic Disease Even with GLP-1 and GIP agonists reshaping diabetes
- HDX-MS-optimized approach to characterize nanobodies as tools for biochemical and structural ...
Overall, our work reveals insight into PI3Kγ regulation and identifies sites that may be exploited for therapeutic
- TLR4 biased small molecule modulators
Biased pharmacological modulators provide potential therapeutic benefits, including greater pharmacodynamic
- The development of modulators for lysophosphatidic acid receptors: A comprehensive review
the current status of ligand development targeting LPA receptors to modulate LPA signaling and their therapeutic
- Do You Believe AI Could Accelerate Drug Discovery?
challenges is crucial to fully harness AI's potential in accelerating drug discovery and optimizing therapeutic
- Integrating Fluorescent Ligands into Flow Cytometry: Enhancing GPCR Analysis Beyond Traditional Antibody Staining
study biased signaling pathways, improving our understanding of GPCR functional diversity and their therapeutic
- Fluorescence Polarization in GPCR Research
compounds that interact with molecular targets involved in disease pathways is where the development of new therapeutics
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
Leverage this model to stay ahead of therapeutic complexity.
- Dynamic GPCR activation revealed through time-resolved Cryo-EM
puzzles and underscores the importance of understanding cellular processes at the molecular level for therapeutic
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic
- GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026
Endocrine Metabolic GPCRs 2026 and Biophysical Society Meeting previews; positive ACCESS data for Structure Therapeutics
- Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic ...
indicated by the fact that about 40% of all drugs currently used in clinical practice mediate their therapeutic
- Rescue of Cell Surface Expression and Signaling of Mutant Follicle-Stimulating Hormone Receptors
advancing the understanding of the effects of genetic mutations on GPCR function and provide a proof of therapeutic
- 📰 GPCR Weekly News, October 9 to 15, 2023
Tethered Ligands that Target the µ-Opioid Receptor Design and Synthesis of Novel GPR139 Agonists with Therapeutic
- Your GPCR Program Decisions Depend on Good Data Interpretation
drug discovery; new strategies for inflammatory disease treatment; growth strategies from Tectonic Therapeutics
- Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled ...
cognate positions across GPCR paralogs opens a window into cancer mechanisms and potential approaches to therapeutics
- 📰 GPCR Weekly News, May 15 to 21, 2023
Hopkins, Exscientia’s founder and CEO was elected a Fellow of the Academy of Medical Sciences Structure Therapeutics
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
Antibodies, Bias, and the Expanding Modality Landscape Antibody therapeutics are now entering spaces
- Understanding Enzyme Inhibition In GPCR Discovery Programs
When “inhibition” becomes activation—and how that insight fuels next-gen therapeutic design.
- Unveiling GPCR Priming: The Hidden Synergy in Cellular Signalling
implications for drug development, as targeting these non-cognate interactions could lead to novel therapeutic
- 📰 GPCR Weekly News, March 18 to 24, 2024
Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease (IBD) Domain Therapeutics
- 📰 GPCR Weekly News - January 2 to 8, 2023
Enter into Multitarget Antibody Discovery Research Collaboration Neurocrine Biosciences and Voyager Therapeutics
- Radioligands vs. Fluorescent Ligands: Binding Assays
On the other hand, fluorescence signals can be easily monitored through confocal microscopy, plate readers
- Interacting binding insights and conformational consequences of the differential activity of...
way for understanding the CBD pharmacology at a molecular level and aid in harnessing its potential therapeutic
- GPCR Collaboration: From Models to Medicine
They offer extraordinary therapeutic promise —but their complexity makes them one of the hardest targets














